REGISTER now for FREE 
|
FREE patent keyword monitoring and additional FREE benefits. REGISTER now for FREE
|
|
|
Drug, Bio-affecting And Body Treating Compositions > Designated Organic Active Ingredient Containing (doai) > Heterocyclic Carbon Compounds Containing A Hetero Ring Having Chalcogen (i.e., O,s,se Or Te) Or Nitrogen As The Only Ring Hetero Atoms Doai > Hetero Ring Is Seven-membered Consisting Of Two Nitrogens And Five Carbon Atoms > Polycyclo Ring System Having The Seven-membered Hetero Ring As One Of The Cyclos > Bicyclo Ring System Having The Seven-membered Hetero Ring As One Of The Cyclos Bicyclo Ring System Having The Seven-membered Hetero Ring As One Of The CyclosBicyclo Ring System Having The Seven-membered Hetero Ring As One Of The Cyclos patent applications listed are from June 2005 to current and include Date, Patent Application Number, Patent Title, Patent Abstract summary and are linked to the corresponding patent application page.01/25/07 - 20070021412 - Treatment of gastrointestinal dysfunction and related stress with an enantiomerically-pure (s) 2,3-benzodiazepine The present invention relates to methods of treatment for symptoms of gastrointestinal dysfunction and related stress that are frequently associated with, for example, irritable bowel syndrome. The symptoms include altered bowel motility, gastrointestinal inflammation, visceral hypersensitivity, or gastric ulcers. ... 01/25/07 - 20070021411 - Supersaturated benzodiazepine solutions and their delivery The invention describes supersaturated solutions of benzodiazepines, such as diazepam, glycofurol and water and their use for intranasal (NS) administration to combat various disorders. ... 12/14/06 - 20060281736 - Product comprising at least one phosphatase cdc25 inhibitor combined with at least one other anticancer agent A subject of the invention is a product comprising at least one Cdc25 phosphatase inhibitor in combination with at least one other anti-cancer agent for a therapeutic use which is simultaneous, separate or spread over time in the treatment of cancer. According to the invention, the other anti-cancer agent is ... 12/07/06 - 20060276457 - Piperazine-piperidines with cxcr3 antagonist activity or a pharmaceutically acceptable salt, solvate or ester thereof, wherein the various moieties are defined herein. Also disclosed is a method of treating chemokine mediated diseases, such as, palliative therapy, curative therapy, prophylactic therapy of certain diseases and conditions such as inflammatory diseases (non-limiting example(s) include, psoriasis), autoimmune diseases (non-limiting ... 11/30/06 - 20060270663 - Substituted 7,8-dihydro-1h-pyrimido[4,5-b][1,4]diazepin-4-amines are novel kinase inhibitors are useful for inhibiting protein tyrosine kinases. The present invention also discloses methods of making the compounds, compositions containing the compounds, and methods of treatment using the compounds. ... 11/23/06 - 20060264421 - Conversion process for 2,3-benzodiazepine enantiomers Methods for the racemization of an enantiomer of a 2,3-benzodiazepine molecule into the corresponding racemic mixture under either basic or acidic conditions are described. Furthermore, the invention relates to the conversion of an enantiomer of tofisopam or its metabolites to the corresponding opposite enantiomer. ... 11/16/06 - 20060258647 - Treatment of maladaptive substance use with cholecystokinin (cck) antagonists The present invention provides a method of mitigating a symptom of maladaptive substance use in a subject by inhibiting CCKB receptors. In addition, the invention provides a variety of prescreening and screening methods aimed at identifying agents that modulate a symptom of maladaptive substance use. Methods of the invention can ... 11/16/06 - 20060258646 - 3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes The pre-sent invention is directed to 3-amino-4-phenylbutanoic acid derivatives which are inhibitors of the dipeptidyl peptidase-IV enzyme (“DP-IV inhibitors”) and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly type 2 diabetes. The invention is also ... 11/09/06 - 20060252750 - Selected cgrp-antagonists, process for preparing them and their use as pharmaceutical compositions wherein A, X, D, E, G, M, Q and R1 to R3 are defined as in claim 1, the tautomers, the isomers, the diastereomers, the enantiomers, the hydrates thereof, the mixtures thereof and the salts thereof and the hydrates of the salts, particularly the physiologically acceptable salts thereof with inorganic ... 10/26/06 - 20060241103 - Inhibitors of ftsz and uses thereof The invention relates to inhibitors of FtsZ polymerization and uses thereof. ... 10/19/06 - 20060235007 - Substituted 1,4-diazepines and uses thereof R6, R7 and R8 are independently hydrogen, alkyl, cycloalkyl, aryl, heteroaryl, a saturated or partially unsaturated heterocycle, cycloalkylalkyl, aralkyl or heteroarylalkyl, each of which is optionally substituted; or R6 and R7, together with the carbon atom to which they are attached form a 3- to 7-membered carbocyclic ring optionally substituted ... 10/19/06 - 20060235006 - Combinations, methods and compositions for treating cancer The invention relates to a combination of BCR-ABL inhibitor, exemplified by ′N-(2-Chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazolecarboxamide and/or other BCR/ABL inhibitors, and a stem cell selective cytotoxic, exemplified by (R)-2,3,4,5-tetrahydro-1-(1H-imidazol-4-ylmethyl)-3-(phenylmethyl)-4-(2-thienylsulfonyl)-1H-1,4-benzodiazepine-7-carbonitrile, hydrochloride salt, and or other stem cell cytotoxic agents, pharmaceutical compositions of the combination and to methods of using the pharmaceutical compositions in the treatment ... 10/12/06 - 20060229301 - Spiro-piperidine compounds and medicinal use thereof wherein R1 represents hydrogen, an aliphatic hydrocarbon group which may have a substituent(s) or a cyclic group which may have a substituent(s); and ring A represents a 5- to 8-membered cyclic group which may have a substituent(s), a salt thereof, an N-oxide thereof, a quaternary ammonium salt thereof or a ... 09/28/06 - 20060217371 - Diazabicyclononene and tetrahydropyriddine derivatives as renin inhibitors The invention relates to novel 3,9-diazabicyclo[3.3.1]nonene derivatives, tetrahydropyridine derivatives, and related compounds and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions containing one or more of those compounds and especially their ... 09/14/06 - 20060205715 - 6-substituted nicotinamide derivatives as opioid receptor antagonists A compound of the formula (I) or a pharmaceutically acceptable salt, enantiomer, racemate, diastereomers or mixtures thereof, or a solvate thereof, formulations and methods of use thereof, as opioid receptor antagonists are disclosed wherein the variables are as described herein. ... 08/31/06 - 20060194795 - Platelet adp receptor inhibitors Novel compounds of formulae (I) to (VIII), which more particularly include sulfonylurea derivatives, sulfonylthiourea derivatives, sulfonylguanidine derivatives, sulfonylcyanoguanidine derivatives, thioacylsulfonamide derivatives, and acylsulfonamide derivatives which are effective platelet ADP receptor inhibitors. These derivatives may be used in various pharmaceutical compositions, and are particularly effective for the prevention and/or treatment of ... 08/24/06 - 20060189600 - Benodiazepine spirohydantoin cgrp receptor antagonists The present invention is directed to compounds that are antagonists of CGRP receptors and that are useful in the treatment or prevention of diseases in which the CGRP is involved, such as headache, migraine and cluster headache. The invention is also directed to pharmaceutical compositions comprising these compounds and the ... 08/03/06 - 20060172998 - Method of preventing relapse in the abstinent substance dependent individual A method of preventing a relapse in the abstinent substance abuse dependent person. The method involves the use of the medication of Flumazenil in a nasal spray device and to teach the person to self-administer the medication by spraying the medication into the nasal passage whenever the need and the ... 07/27/06 - 20060166976 - Compositions and methods for treating or preventing convulsions or seizures The present invention relates to compositions comprising S-tofisopam substantially free of R-tofisopam, and methods for treating or preventing convulsions and/or seizures comprising administration of the composition to subjects in need of treatment therefore. Also provided are compositions and methods for treating or preventing convulsions and/or seizures comprising administering S-tofisopam substantially ... 07/27/06 - 20060166975 - Compositions and methods relating to novel compounds and targets thereof The present invention relates to novel chemical compounds, methods for their discovery, and their therapeutic use. In particular, the present invention provides benzodiazepine derivatives and related compounds and methods of using benzodiazepine derivatives and related compounds as therapeutic agents to treat a number of conditions associated with the faulty regulation ... 07/27/06 - 20060166974 - Azabenzoxazoles for the treatment of cns disorders The present invention relates to α7 nicotinic receptor agonists of formula I as described herein and to a method for treating disorders of the Central Nervous System (CNS) such as cognitive deficits in schizophrenia, by administering to a mammal an α7 nicotinic receptor agonist of formula I as shown herein. ... 07/27/06 - 20060166973 - Organic compounds as agents for the treatment of aldosterone mediated conditions provide pharmacological agents which are inhibitors of the P450 enzyme, aldosterone synthase, and thus may be employed for the treatment of aldosterone mediated conditions. Accordingly, the compounds of formula I may be employed for prevention, delay of progression, or treatment of hypokalemia, hypertension, congestive heart failure, renal failure, in particular, ... 07/13/06 - 20060154921 - Use of cgrp antagonists in treatment and prevention of hot flushes in prostate cancer patients The invention relates to a method of treatment or prevention of hot flushes in men who underwent castration, e.g. due to androgen ablation treatment in prostate cancer therapy, comprising administration of an effective amount of a selected CGRP antagonist to the patient, and to the use of said active compounds ... 07/06/06 - 20060148792 - Substituted 1,4-benzodiazepines and uses thereof R10 is —(CH2)n—CO2Rb, —(CH2)m—CO2M, —(CH2)i—OH or —(CH2)j—CONRcRd n is 0-8, m is 0-8, i is 1-8 and j is 0-8. ... 07/06/06 - 20060148791 - Glutamate receptor antagonists X is an ethynediyl group, R1, R2 and R3 are as defined in the specification. ... 07/06/06 - 20060148790 - Benzodiazepine cgrp receptor antagonists (where variables R1, R2, R3, R6, R7, G, J, W, X and Y are as defined herein) useful as antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which the CGRP is involved, such as headache, migraine and cluster headache. The invention is also directed ... 07/06/06 - 20060148789 - Novel diazabicyclic aryl derivatives This invention relates to novel diazabicyclic aryl derivatives which are found to be cholinergic ligands at the nicotinic acetylcholine receptors. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of ... 06/29/06 - 20060142275 - Prenyl transferase inhibitors or N(R24R25); and the remaining substituents are as defined in the disclosure. ... 06/29/06 - 20060142274 - Use of selected cgrp antagonists for combating menopausal hot flushes The invention relates to the use of selected CGRP antagonists, the physiologically acceptable salts thereof or the hydrates of the hydrates of the salts thereof for combating menopausal hot flushes. ... 06/29/06 - 20060142273 - Use of selected cgrp-antagonists in combination with other antimigraine drugs for the treatment of migraine The present invention relates to a process for the treatment or prevention of indications which are selected from among the group comprising headaches, migraine and cluster headaches, this process comprising the joint administration of a therapeutically effective amount of a selected CGRP antagonist (A), a physiologically acceptable salt thereof or ... 06/22/06 - 20060135511 - Benzodiazepine cgrp receptor antagonists The present invention is directed to compounds of Formula I: I (where variables R1?, R/ 2?, R3?, R 4?, R6?, R7?, G, J, Q, T, U, V, W, X and Y are as defined herein) useful as antagonists of CGRP receptors and useful in the treatment or prevention of diseases ... 06/15/06 - 20060128696 - Treating seizures using ice inhibitors This invention relates to methods and compositions for treating or preventing seizures. ... 06/15/06 - 20060128695 - Cyclic nucleotide phosphodiesterase inhibitors, preparation and uses The invention concerns the use of PDE2 inhibitors for treating disorders of the central and peripheral nervous system, a method for therapeutic treatment by administering to an animal said inhibitors. More specifically, the invention concerns novel benzodiazepinone derivatives and their uses in therapeutics more particularly for treating pathologies involving activity ... 06/08/06 - 20060122172 - Novel 1,4-diazabicycloalkane derivatives, their preparation and use This invention relates to novel 1,4-diazabicycloalkane derivatives and their use in the manufacture of pharmaceutical compositions. The compounds of the invention are found to be cholinergic ligands at the nicotinic acetylcholine receptors and modulators of the monoamine receptors and transporters. Due to their pharmacological profile the compounds of the invention ... 06/01/06 - 20060116367 - Novel [1,4]benzodiazepines as vasopressin v2 receptor antagonists The invention is directed to novel [1,4]benzodiazepine compounds useful as vasopressin receptor antagonists for treating conditions involving increased vascular resistance and cardiac insufficiency. Pharmaceutical compositions comprising [1,4]benzodiazepine compounds of the present invention and methods of treating conditions such as hypertension, congestive heart failure, cardiac insufficiency, coronary vasospasm, cardiac ischemia, liver ... 06/01/06 - 20060116366 - Spirocyclic ureas, compositions containing such compounds and methods of use The present invention relates to spirocyclic ureas, compositions containing such compounds and methods of treatment The compounds are glucagon receptor antagonists and thus are useful for treating, preventing or delaying the onset of type 2 diabetes mellitus. ... 04/13/06 - 20060079515 - Method for the treatment of polycystic kidney disease The present invention provides a method for treating, inhibiting the progression of, or eradicating polycystic kidney disease of in a patient in need thereof which comprises providing to said patient an effective amount of a TACE inhibitor compound in combination with an effective amount of a Src kinase inhibitor, a ... 04/13/06 - 20060079514 - Methods and compositions including methscopolamine bromide Therapeutic pharmaceutical compositions are provided that include an anticholinergic agent and a sedative agent. Particularly preferred anticholinergic agents include anticholinergic agents which do not substantially cross the blood-brain barrier. Methscopolamine bromide is the preferred anticholinergic agent. The sedative agent may be chlordiazepoxide hydrochloride or diazepam. Various methods using the compositions ... 04/13/06 - 20060079513 - Methods and compositions including methscopolamine nitrate Therapeutic pharmaceutical compositions are provided that include an anticholinergic agent and a sedative agent. Particularly preferred anticholinergic agents include anticholinergic agents which do not substantially cross the blood-brain barrier. Methscopolamine nitrate is the preferred anticholinergic agent. The sedative agent may be a benzodiazepine or a barbiturate. Particularly, the sedative agent ... 04/06/06 - 20060074078 - Product comprising a transduction inhibitor of heterotrimeric g protein signals combined with another anti-cancer agent for therapeutic use in the treatment of cancer A composition for treating cancer comprising an anti-tumorally effective amount of a product comprising at least one transduction inhibitor of heterotrimeric G protein signals and at least one other anti-cancer agent selected from the group consisting of prenyltransferase inhibitors, taxol and its analogues, gemcitabine and camptothecin and its analogues, administered ... 04/06/06 - 20060074077 - Pharmaceutical composition for the treatment of athetoid movement A pharmaceutical composition for the treatment of athetoid movement comprising clonazepam or pharmaceutically acceptable salts thereof as an active ingredient are provided, and are useful for the treatment of athetoisis without any tolerance and adverse effect. ... 03/30/06 - 20060069087 - Histamine-3 receptor antagonists as defined herein, or a pharmaceutically acceptable salt thereof; a pharmaceutical composition containing a compound of formula I, a method of treatment of a disorder or condition that may be treated by antagonizing histamine H3 receptors, the method comprising administering to a mammal in need of such treatment a compound ... 03/09/06 - 20060052369 - Compositions and methods relating to novel compounds and targets thereof The present invention relates to novel chemical compounds, methods for their discovery, and their therapeutic use. In particular, the present invention provides benzodiazepine derivatives and related compounds and methods of using benzodiazepine derivatives and related compounds as therapeutic agents to treat a number of conditions associated with the faulty regulation ... 03/09/06 - 20060052368 - Aryl-substituted diazabicycloalkanes as nicotinic acetylcholine agonists wherein a, b, c, D and R are as defined in the specification, enantiomers, pharmaceutically-acceptable salts, methods of making, pharmaceutical compositions containing and methods for using the same. ... 02/23/06 - 20060040924 - Derivatives of aryl (or heteroaryl) azolylcarbinols for the treatment of renal colic The present invention refers to the use of derivatives of aryl (or heteroaryl) azolylcarbinols of general formula (I), and their physiologically acceptable salts, as medicinal products for human and/or animal therapeutics for the treatment of renal colic. ... 02/23/06 - 20060040923 - Benzodiazepine derivatives and pharmaceutical compositions containing them Benzodiazepine derivative of formula (I), and pharmaceutically acceptable salts thereof, are found to be active against RSV. Formula (I) Wherein: —R1 represents C1-6 alkyl, aryl or heteroaryl; —R2 represents hydrogen or C1-6 alkyl; —each R3 is the same or different and represents halogen, hydroxy, C1-6 alkyl, C1-6 alkoxy, C1-6 alkylthio, ... 02/02/06 - 20060025407 - Succinoylaminobenzodiazepines as inhibitors of abeta protein production to their pharmaceutical compositions and to their methods of use. These novel compounds inhibit the processing of amyloid precursor protein and, more specifically, inhibit the production of Aβ-peptide, thereby acting to prevent the formation of neurological deposits of amyloid protein. More particularly, the present invention relates to the treatment of ... 01/26/06 - 20060019946 - 3-(4-piperidinyl)-2,3,4,5-tetrahydro-1,3-benzodiazepin-2(1h)-one which is to be found as a structural element in CGRP-antagonists, which are particularly suitable for the oral treatment of migraine. ... 01/12/06 - 20060009447 - Pharmaceutical compositions comprising midazolam in a high concentration Compositions of midazolam, a benzodiazapine, in concentrations of 35-100 mg/ml are disclosed for the treatment of anxiety, epilepsy and epileptic seizures, invasive surgical procedures and diagnostic procedures and sedation. These compositions are particularly characterized by a solubilizer such an propylene glycol. Preferably, the compositions are aqueous solutions for intranasal administration. ... 01/05/06 - 20060003995 - Stereospecific anxiolytic and anticonvulsant agents with reduced muscle-relaxant, sedative-hypnotic and ataxic effects The present invention provides compositions and methods of using stereospecific benzodiazepine derivatives, their salts and prodrugs for the treatment of anxiolytic or convulsant disorders having the side effects of reduced alcohol craving in human alcoholics and a concomitant reduced sedative, hypnotic, muscle relaxant and ataxic side-effects. The invention further provides ... 01/05/06 - 20060003994 - Pyrrolo[2,1-c][1,4]benzodiazepine-napthalimide conjugates linked through piperazine moiety and process for preparation thereof The present invention relates to novel pyrrolo[2,1-c][1,4]benzodiazepine-napthalimide hybrids linked through piperazine moiety as potential antitumour agents. The present invention also relates to a process for the preparation of novel pyrrolo[2,1-c][1,4]benzodiazepine-napthalimide hybrids linked through piperazine moiety useful as potential antitumour agents. ... 01/05/06 - 20060003993 - Benzotriazepnes as gastrin and cholecystokinin receptor ligands This invention relates to a compound of formula (I) wherein: W is N or N+—O−; and R1 to R5 are as defined in the description, for use for the treatment of gastrin related disorders. ... 12/29/05 - 20050288278 - Hiv replication inhibiting pyrimidines the N-oxides, the pharmaceutically acceptable addition salts, quaternary amines and the stereochemically isomeric forms thereof, wherein -a1=a2-a3=a4- forms a phenyl, pyridinyl, pyrimidinyl, pyridazinyl or pyrazinyl with the attached vinyl group; n is 0 to 4; and where possible 5; R1 is hydrogen, aryl, formyl, C1-6alkylcarbonyl, C1-6alkyl, C1-6alkyloxy-carbonyl, substituted C1-6alkyl, or ... 12/29/05 - 20050288277 - Treatment of gastrointestinal dysfunction and related stress with an enantiomerically-pure (s)-2,3-benzodiazepine The present invention relates to methods of treatment for symptoms of gastrointestinal dysfunction and related stress which are frequently associated with, for example, irritable bowel syndrome. The symptoms include altered bowel motility, gastrointestinal inflammation, visceral hypersensitivity, or gastric ulcers. ... 12/08/05 - 20050272723 - Methods and compositions for treating diseases and conditions associated with mitochondrial function The present invention relates to chemical compounds, methods for their discovery, and their therapeutic use. In particular, the present invention provides compounds as therapeutic agents to treat a number of conditions associated with the faulty regulation of the processes of programmed cell death, autoimmunity, inflammation, hyperproliferation, mitochondrial F1F0 ATP hydrolase ... 12/08/05 - 20050272722 - Methods for the treatment of synucleinopathies Methods are provided of treating synucleinopathies, such as Parkinson's Disease, Diffuse Lewy Body Disease and Multiple System Atrophy, comprising administering to a synucleinopathic subject a farnesyl transferase inhibitor compound. ... 12/01/05 - 20050267102 - Inhibition of matrix metalloproteases by substituted biaryl oxobutyric acids These compounds are useful for inhibiting matrix metalloproteases and, therefore, combating conditions to which MMP's contribute, such as osteoarthritis, rheumatoid arthritis, septic arthritis, periodontal disease, comeal ulceration, proteinuria, aneurysmal aortic disease, dystrophobic epidermolysis, bullosa, conditions leading to inflammatory responses, osteopenias mediated by MMP activity, tempero mandibularjoint disease, demyelating diseases of ... 12/01/05 - 20050267101 - Treatment of diseases using ice inhibitors This invention relates to methods and compositions for treating autoinflammatory diseases. The invention also assays for evaluating the ability of an ICE inhibitor to treat autoinflammatory diseases. ... 11/24/05 - 20050261282 - Treatment of basal ganglia-related movement disorders with 2,3-benzodiazepines The present invention relates to compounds, related to 2,3 benzodiazepines, of general formula (I), such as Tofisopam, Girisopam or Nerisopam, for use in the treatment of dyskinesia. The dyskinesia may arise as a side-effect of a therapy for pakinsonism. ... 10/27/05 - 20050239774 - Biaryl diazabicycloalkane amides as nicotinic acetylcholine agonists wherein A, D, Ar1, E and Ar2 are as described in the specification, diastereoisomers, enantiomers, pharmaceutically-acceptable salts, methods of making, pharmaceutical compositions containing and methods for using the same. ... 10/27/05 - 20050239773 - Diazabicyclonane and-decane derivatives and their use as opioid receptor ligands This invention relates to novel diazabicyclononane and -decane derivatives useful as opioid receptor ligands. More specifically, the invention provides compounds useful as μ opioid receptor ligands. ... 10/20/05 - 20050234048 - Glutamate receptor antagonists X is an ethynediyl group, R1, R2 and R3 are as defined in the specification. ... 10/13/05 - 20050227968 - Selected cgrp-antagonists process for preparing them and their use as pharmaceutical compositions wherein A, B, D, E, X, R1 and R2 are defined as in claim 1, the tautomers, the diastereomers, the enantiomers, the hydrates thereof, the mixtures thereof and the salts thereof and the hydrates of the salts, particularly the physiologically acceptable salts thereof with inorganic or organic acids, pharmaceutical compositions ... 10/06/05 - 20050222136 - Active substance combination The present invention relates to an active substance combination including at least one substituted carbinol compound and at least one non-steroidal anti-inflammatory drug (NSAID), a medicament including the active substance combination, a pharmaceutical formulation including the active substance combination and the use of the active substance combination for the manufacture ... 10/06/05 - 20050222135 - Active substance combination The present invention relates to an active substance combination comprising at least one substituted carbinol compound and at least one opioid, a medicament comprising said active substance combination, a pharmaceutical formulation comprising said active substance combination and the use of said active substance combination for the manufacture of a medicament. ... 09/29/05 - 20050215546 - Novel substituted piperidines, pharmaceutical compositions containing these compounds, their use and processes for the preparation thereof wherein R, R2 to R5, A, X, Z and n are defined as in claim 1, the tautomers, diastereomers, enantiomers, mixtures and salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases which have valuable pharmacological properties, particularly CGRP-antagonistic properties, pharmaceutical compositions containing these compounds, ... 09/22/05 - 20050209219 - Prophylaxis and treatment of infectious diseases The invention relates to the use of inhibitors of acid sphingomyelinase and/or inhibitors of products of the reaction catalysed by said enzyme, for the prophylaxis and/or treatment of infectious diseases and/or diseases which are influenced by infections during the course thereof. The cited products especially include ceramide. Preferably neutralising antibodies ... 09/01/05 - 20050192272 - Substituted benzodiazepines as inhibitors of the chemokine receptor cxcr4 Compositions and methods that can be used to prevent HIV infection are described. In particular, methods for inhibiting HIV infectivity are provided, which comprise administering to a patient a therapeutically-effective amount of at least one CXCR4 receptor-binding composition described herein. The CXCR4 receptor-binding compositions useful in the present invention include ... 08/11/05 - 20050176700 - 7-aryl-3,9-diazabicyclo(3.3.1)non-6-ene derivatives and their use as renin inhibitors in the treatment of hypertension,cardiovascular or renal diseases The invention relates to novel 3,9-diazabicyclo[3.3.1]nonene derivatives of formula (I) and related compounds and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions containing one or more of those compounds and especially ... 08/11/05 - 20050176699 - Benzodiazepine derivatives, preparation thereof and use thereof Compounds of Formula (I) wherein R1, R3, R4, R5 and X are as defined in the specification, as well as salts, enantiomers thereof and pharmaceutical compositions including the compounds are prepared. They are useful in therapy, in particular in the management of pain. ... 07/21/05 - 20050159409 - Fused bicyclic pyrimidine derivatives wherein the rings A and B are each a benzene ring having 1 to 3 substituents (any adjacent two of which may be bound to one another to form a ring); the ring C is a nitrogen-containing ring; R is a hydrogen atom, a C1 to C6 alkyl group, a ... 07/14/05 - 20050153956 - Pharmaceutical compositions comprising midazolam in a high concentration Compositions of midazolam, a benzodiazapine, in concentrations of 35-100 mg/ml are disclosed for the treatment of anxiety, epilepsy and epileptic seizures, invasive surgical procedures and diagnostic procedures and sedation. These compositions are particularly characterized by a solubilizer such an propylene glycol. Preferably, the compositions are aqueous solutions for intranasal administration. ... 06/16/05 - 20050130957 - Novel substituted pyrazolo[4,3-e]diazepines, pharmaceutical compositions containing them, use as medical products and processes for preparing them to pharmaceutical compositions containing them, to their use as medicinal products and to processes for preparing them. ... 06/09/05 - 20050124605 - Novel benzo-fused heterocycles as endothelin antagonisits The invention relates to novel benzo-fused heterocycles and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions containing one or more of those compounds and especially their use as endothelin receptor antagonists. ... ### FreshPatents.com Support |